IDH1 and central nervous system cancer: (1) have published the practice-changing results of the phase 3 INDIGO trial reporting that vorasidenib, a dual IDH1/2 inhibitor, significantly improves the progression free survival (PFS) and prolong the time to next intervention (TTNI) in a cohort of young adults with recurrent or progressive IDH1/2-mutant grade 2 gliomas.